Dr. Reddy’s Laboratories Q3 Outlook **Executive Summary** Dr. Reddy’s Laboratories is anticipated to report a subdued performance for the quarter ending December. Consensus estimates point to a contraction in both revenue and Profit After Tax (PAT), as headwinds in the North American market overshadow gains elsewhere. **Key Performance Drivers** * **US Business Headwinds:** The primary drag on performance stems from the US segment, which is grappling with persistent pricing pressures and a declining contribution from **gRevlimid**. * **Steady Non-US Growth:** Operations in **India and Europe** are expected to maintain a steady growth trajectory. However, positive momentum in these regions is projected to be fully offset by the weakness in the US portfolio.